News Updates
More Articles
- Vaccine makers to produce human bird flu vaccines
- Automated stem cell production system undergoes testing
- FDA OKs Novartis' low-grade glioma drug combo for kids
- Grants support biomanufacturing partnerships in Australia
- Takeda Oncology aims for more partnership to grow its pipelines
Sanofi buys Provention Bio in $2.9B deal
Provention Bio will be acquired by Sanofi for $2.9 billion, granting the company access to Tzield, or teplizumab-mzwv, an FDA-approved prevention therapy for type 1 diabetes, for which they already have a co-promotion deal, as well as some assets for immune-mediated diseases that are in the early drug development phase. As part of the deal, Sanofi will purchase all of Provention Bio's outstanding shares in cash at $25 per share. PMLive (UK) (3/13)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!